Q4 2024 Profound Medical Corp Earnings Call Transcript
Key Points
- Profound Medical Corp (PROF) reported a record revenue of $4.2 million for Q4 2024, marking a 108% increase from the same period in 2023.
- The company achieved a gross margin of 71% in Q4 2024, a significant improvement from 52% in Q4 2023.
- Profound Medical Corp (PROF) reduced its net loss by 45% compared to the same quarter in the previous year.
- The company ended 2024 with a strong cash position of $54.9 million.
- Profound Medical Corp (PROF) is on track with its captain randomized trial, having met its enrollment target, which could enhance its market position and reimbursement acceptance.
- Total operating expenses increased to $11.3 million in Q4 2024 from $9.8 million in Q4 2023, indicating rising costs.
- Despite improvements, the company still recorded a net loss of $4.9 million for Q4 2024.
- The company did not meet its target of reaching 75 sites by the end of 2024.
- Profound Medical Corp (PROF) is transitioning to a capital sales model, which may present challenges in predictability and execution.
- There is uncertainty regarding the timing and extent of payments from Medicare and private insurers, which could impact cash flow.
Thank you for standing by and welcome to the Profound Medical fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions) As a reminder, today's program is being recorded.
And now I'd like to introduce your host for today's program, Stephen Kilmer, Investor Relations. Please go ahead, sir.
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada.
All forward-looking statements are based on profound current beliefs, assumptions, and expectations and relate to, among other things, any expressed or implied statements or guidance regarding current or financial performance and position, the expectations regarding the efficacy of profound technology in the treatment of prostate cancer, BPH, uterine uterine fibroids, palliative pain treatment, and osteoid osteoma, and its future revenues financial results.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
